Sionna Therapeutics, Inc. (NasdaqGM: SION)
Health Care · Biotechnology · US
$4.90
-0.20% today · -83.2% 1Y
Sionna Therapeutics, Inc. (NasdaqGM: SION) operates in the Biotechnology industry within the Health Care sector. The company is valued at $221.99M and employs 59 people.
Over the last twelve months the share price has lost 83.2%, trading between 4.01 and 54.97.
Tweenvest scores Sionna Therapeutics, Inc. across four factors: quality 49/100, value 22/100. Its strongest factor is quality.
SION price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $221.99M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.17
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $54.97
- 52-week low
- $4.01
- Avg volume (3M)
- —
- Shares outstanding
- 45.21M
- Employees
- 59
- Next earnings
- —
About Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
- ISIN
- US8294011080
- Founded
- 2019
- Listed since
- Feb 7, 2025
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| HansBiomed CorporationKOSDAQ: A042520 | $225.02M | ₩21,250.00 | +19.52% |
| Beijing Biostar Pharmaceuticals Co., Ltd.SEHK: 2563 | $224.41M | HK$4.83 | +13.65% |
| Cartesian Therapeutics, Inc.NasdaqGM: RNAC | $222.68M | $6.82 | -7.34% |
| Genomictree Inc.KOSDAQ: A228760 | $222.35M | ₩12,200.00 | +10.91% |
| Compugen Ltd.NasdaqCM: CGEN | $218.81M | $2.12 | -8.23% |
| Protalix BioTherapeutics, Inc.NYSEAM: PLX | $217.54M | $2.70 | -0.37% |
| Guangzhou Innogen Pharmaceutical Group Co., LtdSEHK: 2591 | $217.14M | HK$3.73 | -3.49% |
| Obigen Pharma Inc.TPEX: 7876 | $216.11M | NT$64.20 | +28.40% |
Figures last refreshed Oct 4, 2026.